LETTER TO THE EDITOR

CGRP in migraine

Peer Tfelt-Hansen · Messoud Ashina

Received: 2 June 2009/Accepted: 23 June 2009/Published online: 19 August 2009 © Springer-Verlag 2009

Dear Editor,

Concentrations of substances in plasma, in this case CGRP, can be presented in several different to ways, such as pmol/l [1–7], pg/ml [8, 9] and just recently as ng/ml [10]. These different concentrations can be compared when one uses the molecular weight of 3,790 for CGRP but it takes 5–10 min of arithmetic to do that. When you normally read a paper you do not stop and do the arithmetic needed in order to check the concentrations.

In a recent paper in *Journal of Headache and Pain*, the plasma concentration of CGRP in cubital blood is given as 1.03 ng/ml in migraine [10]. This looks apparently reliable, but when the concentration in pmol/l, the standard way of presenting CGRP concentrations [1–7], is calculated the resulting concentration is 272 pmol/l. This was in migraine patients in the cubital vein outside attacks [10] and the CGRP levels are higher than any CGRP levels reported before both in external jugular blood [1–5], and cubital blood [6–9]. The authors state that the analyses were done with a commercially available ELISA kit and that the kit had a good sensitivity (range 0–25 ng/ml), but the detection limit for CGRP is not stated.

The best way to avoid such problems is to present CGRP levels in pmol/l. One can then easily skim the literature and compare results in different studies.

A reply to this letter can be found at doi:10.1007/s10194-009-0141-3.

P. Tfelt-Hansen (☑) · M. Ashina Department of Neurology, Danish Headache Centre, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark e-mail: ptha@glo.regionh.dk

References

- Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine attacks. Ann Neurol 28:183–187
- Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56
- Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J (2005) No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58:561–563
- Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S (1995) Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitro-glycerin-induced cluster headache attack. Pain 60:119–123
- Fanciullacci M, Alessandri M, Sicuteri R, Marabini S (1997) Responsiveness of the trigeminovascular system to nitroglycerin in cluster headache patients. Brain 120:283–288
- Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J (2000) Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside attacks. Pain 86:133–138
- Gallai V, Sarchielli P, Floridi A, Franceshini M, Codini M, Glioti G et al (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384–390
- Fan P-C, Kuo P-H, Chang S-H, Lee W-T, Wu R-M, Chiou L-C (2009) Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia 29:883–990
- Fusayasu E, Kowa T, Takeshima T, Nakaso K, Nahashima K (2007) Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 128:209–214
- Gupta R, Ahmed T, Banerjee B, Bhatia M (2009) Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension-type headache subjects during inter-ictal period. J Headache Pain 10:161–166

